Arlington Center for Dermatology

Recent papers from Arlington Center for Dermatology

1. Host contributions to Borrelia burgdorferi (Spirochaetales: Spirochaetaceae) infection prevalence in Ixodes scapularis (Acari: Ixodidae) nymphsJournal of Medical Entomology · 2026
2. Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summaryJournal of Dermatological Treatment · 2026
3. Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb TrialDermatology and Therapy · 2026
4. Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful TrialDermatology and Therapy · 2026
5. Reimagining U.S. social care policy: a commentary on Medicaid strategies to better support individuals with dementiaFrontiers in Dementia · 2026
6. Double Trouble: Bilateral Fishbone Perforation and Its Successful RetrievalACG Case Reports Journal · 2026
7. Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)American Journal of Clinical Dermatology · 2026
8. Oral Icotrokinra for Plaque Psoriasis in Adults and AdolescentsNew England Journal of Medicine · 2025
9. Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 WeeksAmerican Journal of Clinical Dermatology · 2025
10. Addressing maternal cardiovascular risk: The impact of lactation, adverse pregnancy outcomes, and racial disparitiesAmerican Heart Journal Plus Cardiology Research and Practice · 2025
11. Multimodal Autonomous Delivery Systems: Pilot Study of Middle- and Last-Mile IntegrationIEEE Systems Man and Cybernetics Magazine · 2025
12. Acne Conglobata: Understanding This Rare Form of Acne and Management StrategiesDermatology and Therapy · 2025
13. Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable StudyAmerican Journal of Clinical Dermatology · 2025
14. Correlation of tocilizumab vs baricitinib with secondary bacterial and fungal infections in patients with COVID-19American Journal of Health-System Pharmacy · 2025
15. Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin TonesJAMA Dermatology · 2025
16. Severe Hypokalemic Paralysis Following Rituximab Infusion in a Patient With Microscopic PolyangitisCureus · 2025
17. A silent opponent: Staphylococcus aureus and its impact on wrestlersInternational Journal of Sports Medicine · 2025
18. Recommendations to Improve Outcomes in Acne and Acne Sequelae: A Focus on Trifarotene and Other RetinoidsDermatology and Therapy · 2025
19. Perceptions and reflections of embryo donation recipients: a qualitative follow-up studyGynecology and Obstetrics Clinical Medicine · 2025
20. Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and ChildrenJAMA Dermatology · 2024